Cases and


Webinar “Findings during the inspections of Federal Service for Surveillance in Healthcare (Roszdravnadzor) in 2016”

What will we discuss in Webinar?

The review of Roszdravnadzor findings in 2016 along with its classification, analysis, possible corrective and/or preventive actions.

For whom?

For drug developers, pharmaceutical and biotech companies, participants of the clinical trial market, doctors.


Konstantin Semenov, IPHARMA QA Director

Vyacheslav Rogov, IPHARMA Administrative director

© 2020 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon